PapersFlow Research Brief
Autoimmune and Inflammatory Disorders Research
Research Guide
What is Autoimmune and Inflammatory Disorders Research?
Autoimmune and Inflammatory Disorders Research is a field in hematology that studies hemophagocytic syndromes such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome, including their diagnostic guidelines, therapeutic approaches, genetic mutations, cytokine involvement, and treatment efficacy in pediatric and adult patients.
The field encompasses 44,247 published works on topics like HLH, juvenile idiopathic arthritis, and macrophage activation syndrome. It examines pathogenesis, classification criteria, and long-term outcomes, with associations to conditions such as systemic-onset juvenile idiopathic arthritis. Key focuses include HLH-2004 guidelines, etoposide treatment, perforin gene mutations, and interleukin-1 blockade.
Topic Hierarchy
Research Sub-Topics
Hemophagocytic Lymphohistiocytosis Diagnostic Criteria
This sub-topic covers the development, validation, and application of diagnostic guidelines such as HLH-2004 for identifying hemophagocytic lymphohistiocytosis in pediatric and adult patients. Researchers study clinical scoring systems, biomarker thresholds, and differential diagnosis from mimicking conditions.
Familial Hemophagocytic Lymphohistiocytosis Genetic Mutations
This sub-topic examines genetic defects in genes like PRF1, UNC13D, and STX11 underlying familial forms of HLH. Researchers investigate mutation spectra, genotype-phenotype correlations, and implications for hematopoietic stem cell transplantation.
Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
This sub-topic focuses on the pathogenesis, triggers, and management of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Researchers analyze cytokine profiles, diagnostic criteria like MAS-HLH 2016, and response to therapies like anakinra.
Cytokine Storm in Hemophagocytic Syndromes
This sub-topic explores hypercytokinemia involving IL-6, IL-1, IFN-γ, and other mediators driving HLH pathogenesis. Researchers study cytokine dynamics, blockade therapies, and links to infections like COVID-19.
Etoposide-Based Therapy for Hemophagocytic Lymphohistiocytosis
This sub-topic addresses protocols using etoposide in HLH-2004 regimens, efficacy in primary vs secondary HLH, and toxicity management. Researchers evaluate treatment outcomes, salvage therapies, and bridging to definitive hematopoietic stem cell transplantation.
Why It Matters
Research in this field guides clinical management of life-threatening hemophagocytic syndromes, as shown in "HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis" (Henter et al., 2006), which updated diagnosis from five criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis) by adding three more and established prospective treatment protocols used internationally. In rheumatoid arthritis, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update" (Smolen et al., 2017) provides evidence-based strategies for synthetic and biological drugs, improving patient outcomes across 5703 citations. Cytokine research, such as "COVID-19: consider cytokine storm syndromes and immunosuppression" (Mehta et al., 2020) with 10031 citations, links HLH-like cytokine storms to COVID-19, influencing immunosuppressive therapies that reduced mortality in severe cases.
Reading Guide
Where to Start
"HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis" (Henter et al., 2006) because it provides foundational criteria and protocols central to the cluster, cited 5116 times with clear diagnostic and treatment steps.
Key Papers Explained
"COVID-19: consider cytokine storm syndromes and immunosuppression" (Mehta et al., 2020, 10031 citations) highlights HLH-like storms, linking to mechanisms in "Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death" (Shi et al., 2015, 6153 citations) and "Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling" (Kayagaki et al., 2015, 3496 citations), which detail pyroptosis pathways. "HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis" (Henter et al., 2006, 5116 citations) applies these to clinical HLH management. "IL-6 in Inflammation, Immunity, and Disease" (Tanaka et al., 2014, 4677 citations) connects cytokine roles to rheumatic disorders like those in "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update" (Smolen et al., 2017, 5703 citations).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers emphasize inflammasome inhibition via GSDMD and caspase pathways from Shi et al. (2015) and Kayagaki et al. (2015), with ongoing needs for adult HLH trials building on Henter et al. (2006). No recent preprints available, but cluster keywords point to perforin mutations and etoposide optimization.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | COVID-19: consider cytokine storm syndromes and immunosuppression | 2020 | The Lancet | 10.0K | ✓ |
| 2 | Cleavage of GSDMD by inflammatory caspases determines pyroptot... | 2015 | Nature | 6.2K | ✕ |
| 3 | Modified disease activity scores that include twenty-eight-joi... | 1995 | Arthritis & Rheumatism | 6.1K | ✕ |
| 4 | EULAR recommendations for the management of rheumatoid arthrit... | 2017 | Annals of the Rheumati... | 5.7K | ✓ |
| 5 | HLH‐2004: Diagnostic and therapeutic guidelines for hemophagoc... | 2006 | Pediatric Blood & Cancer | 5.1K | ✕ |
| 6 | IL-6 in Inflammation, Immunity, and Disease | 2014 | Cold Spring Harbor Per... | 4.7K | ✓ |
| 7 | Rheumatoid arthritis | 2016 | The Lancet | 4.4K | ✕ |
| 8 | International League of Associations for Rheumatology classifi... | 2004 | PubMed | 4.2K | ✕ |
| 9 | Hematological Problems in Pediatric Intensive Care | 2013 | Pediatric and adolesce... | 3.5K | ✕ |
| 10 | Caspase-11 cleaves gasdermin D for non-canonical inflammasome ... | 2015 | Nature | 3.5K | ✕ |
Frequently Asked Questions
What are the diagnostic criteria for hemophagocytic lymphohistiocytosis?
HLH-2004 guidelines specify eight criteria: fever, splenomegaly, cytopenias affecting at least two lineages, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis, low or absent NK cell activity, hyperferritinemia, and elevated soluble CD25. Diagnosis requires either a molecular mutation consistent with HLH or five of eight criteria. These build on HLH-94 by adding three criteria for improved accuracy (Henter et al., 2006).
How does IL-6 contribute to inflammatory disorders?
IL-6 is produced promptly in response to infections and tissue injuries, stimulating acute phase responses, hematopoiesis, and immune reactions. Its expression is controlled by transcriptional and posttranscriptional mechanisms. Dysregulated IL-6 drives chronic inflammation in autoimmune diseases (Tanaka et al., 2014).
What is macrophage activation syndrome?
Macrophage activation syndrome is an HLH-related disorder often associated with juvenile idiopathic arthritis, particularly systemic-onset forms. It involves cytokine overproduction and hemophagocytosis. Treatment includes etoposide and interleukin-1 blockade per cluster keywords.
What are the EULAR recommendations for rheumatoid arthritis management?
EULAR 2016 update recommends synthetic and biological disease-modifying antirheumatic drugs based on disease phase and risk. These include methotrexate as first-line, with biologics for inadequate response. The guidelines are validated for long-term efficacy (Smolen et al., 2017).
How was juvenile idiopathic arthritis classified in 2001?
The International League of Associations for Rheumatology classified juvenile idiopathic arthritis into subtypes like systemic, oligoarticular, and polyarticular based on onset features and exclusions. This second revision from Edmonton standardized global research and diagnosis (Petty et al., 2004).
What role does GSDMD play in pyroptosis?
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death, releasing inflammatory contents. This process is central to inflammasome signaling in autoimmune inflammation. GSDMD pores execute the lytic death (Shi et al., 2015).
Open Research Questions
- ? How can non-canonical inflammasome pathways involving caspase-11 and gasdermin D be targeted to prevent pyroptosis in HLH?
- ? What genetic mutations beyond perforin drive familial hemophagocytic lymphohistiocytosis outcomes?
- ? How do cytokine storm profiles differ between COVID-19 and primary HLH, informing immunosuppression?
- ? Which therapeutic combinations optimize etoposide with interleukin-1 blockade in macrophage activation syndrome?
- ? What long-term prognostic factors predict survival in adult-onset HLH associated with rheumatic diseases?
Recent Trends
The field holds 44,247 works with sustained focus on HLH-2004 guidelines (Henter et al., 2006) and cytokine mechanisms, as seen in top-cited papers like Mehta et al. applying HLH concepts to COVID-19 with 10031 citations.
2020No growth rate data or recent preprints/news available, maintaining emphasis on genetic mutations and treatments like etoposide.
Research Autoimmune and Inflammatory Disorders Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Autoimmune and Inflammatory Disorders Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers